Abstract
The Warburg effect, a widely known characteristic of cancer cells, refers to the utilization of glycolysis under aerobic conditions for extended periods of time. Recent studies have revealed that cancer cells are capable of reprogramming their metabolic pathways to meet vigorous metabolic demands. New anticancer drugs that target the complicated metabolic systems of cancer cells are being developed. Identifying the potential targets of novel compounds that affect cancer metabolism may enable the discovery of new therapeutic targets for cancer treatment, and hasten the development of anticancer drugs. Historically, various drug screening techniques such as the analysis of a compound’s antiproliferative effect on cancer cells and proteomic methods, that enable target identification have been used to obtain many useful drugs from natural products. Here, we review proteomics-based target identification methods applicable to natural products that affect cancer metabolism.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933–9.
Vasan K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32:341–52.
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–34.
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890–901.
Peeters TH, Lenting K, Breukels V, van Lith SAM, van den Heuvel C, Molenaar R, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019;7:4.
Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014;4:1290–8.
Golub D, Iyengar N, Dogra S, Wong T, Bready D, Tang K, et al. Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics. Front Oncol. 2019;9:417.
Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036–46.
Alalem M, Ray A, Ray BK. Metformin induces degradation of mTOR protein in breast cancer cells. Cancer Med. 2016;5:3194–204.
Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an anticancer agent. Trends Pharm Sci. 2018;39:867–78.
Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.
Horgan DJ, Ohno H, Singer TP. Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XV. Interactions of piericidin with the mitochondrial respiratory chain. J Biol Chem. 1968;243:5967–76.
Miyadera H, Shiomi K, Ui H, Yamaguchi Y, Masuma R, Tomoda H, et al. Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). Proc Natl Acad Sci USA. 2003;100:473–7.
Berry EA, Huang LS, Lee DW, Daldal F, Nagai K, Minagawa N. Ascochlorin is a novel, specific inhibitor of the mitochondrial cytochrome bc1 complex. Biochim Biophys Acta. 2010;1797:360–70.
Tamura G, Suzuki S, Takatsuki A, Ando K. Arima K. Ascochlorin, a new antibiotic, found by the paper-disc agar-diffusion method. I. Isolation, biological and chemical properties of ascochlorin. (Studies on antiviral and antitumor antibiotics. I). J Antibiot. 1968;21:539–44.
Joshi S, Huang YG. ATP synthase complex from bovine heart mitochondria: the oligomycin sensitivity conferring protein is essential for dicyclohexyl carbodiimide-sensitive ATPase. Biochim Biophys Acta. 1991;1067:255–8.
Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem. 2009;52:6752–6.
Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M, et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene. 2002;21:6082–90.
Momose I, Ohba S, Tatsuda D, Kawada M, Masuda T, Tsujiuchi G, et al. Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions. Biochem Biophys Res Commun. 2010;392:460–6.
Reckzeh ES, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1-4. Chembiochem. 2020;21:45–52.
Kitagawa M, Ikeda S, Tashiro E, Soga T, Imoto M. Metabolomic identification of the target of the filopodia protrusion inhibitor glucopiericidin A. Chem Biol. 2010;17:989–98.
Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10:eaat5933.
Kondoh Y, Honda K, Osada H. Construction and application of a photo-cross-linked chemical array. Methods Mol Biol. 2015;1263:29–41.
Asmari M, Ratih R, Alhazmi HA, El Deeb S. Thermophoresis for characterizing biomolecular interaction. Methods. 2018;146:107–19.
Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297–306.
Kanoh N, Honda K, Simizu S, Muroi M, Osada H. Photo-cross-linked small-molecule affinity matrix for facilitating forward and reverse chemical genetics. Angew Chem Int Ed Engl. 2005;44:3559–62.
Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M, et al. High-performance affinity beads for identifying drug receptors. Nat Biotechnol. 2000;18:877–81.
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.
Sato S, Murata A, Shirakawa T, Uesugi M. Biochemical target isolation for novices: affinity-based strategies. Chem Biol. 2010;17:616–23.
Kanoh N, Takayama H, Honda K, Moriya T, Teruya T, Simizu S, et al. Cleavable linker for photo-cross-linked small-molecule affinity matrix. Bioconjug Chem. 2010;21:182–6.
Jung HJ, Shim JS, Lee J, Song YM, Park KC, Choi SH, et al. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced reactive oxygen species production and cellular oxygen sensing. J Biol Chem. 2010;285:11584–95.
Wada A, Hara S, Osada H. Ribosome display and photo-cross-linking techniques for in vitro identification of target proteins of bioactive small molecules. Anal Chem. 2014;86:6768–73.
Dai L, Li Z, Chen D, Jia L, Guo J, Zhao T et al. Target identification and validation of natural products with label-free methodology: a critical review from 2005 to 2020. Pharmacol Ther. 2020;216:107690.
Ha J, Park H, Park J, Park SB. Recent advances in identifying protein targets in drug discovery. Cell Chem Biol. 2020;28:394–423.
Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci USA. 2009;106:21984–9.
Dal Piaz F, Vera Saltos MB, Franceschelli S, Forte G, Marzocco S, Tuccinardi T, et al. Drug affinity responsive target stability (DARTS) identifies laurifolioside as a new clathrin heavy chain modulator. J Nat Prod. 2016;79:2681–92.
Vasaturo M, Cotugno R, Fiengo L, Vinegoni C, Dal Piaz F, De Tommasi N. The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells. Sci Rep. 2018;8:16735.
Geer Wallace MA, Kwon DY, Weitzel DH, Lee CT, Stephenson TN, Chi JT, et al. Discovery of manassantin A protein targets using large-scale protein folding and stability measurements. J Proteome Res. 2016;15:2688–96.
Kasper AC, Moon EJ, Hu X, Park Y, Wooten CM, Kim H, et al. Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations. Bioorg Med Chem Lett. 2009;19:3783–6.
Savitski MM, Reinhard FB, Franken H, Werner T, Savitski MF, Eberhard D, et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science. 2014;346:1255784.
Park H, Ha J, Koo JY, Park J, Park SB. Label-free target identification using in-gel fluorescence difference via thermal stability shift. Chem Sci. 2017;8:1127–33.
Nagasawa I, Muroi M, Kawatani M, Ohishi T, Ohba SI, Kawada M, et al. Identification of a small compound targeting PKM2-regulated signaling using 2D gel electrophoresis-based proteome-wide CETSA. Cell Chem Biol. 2020;27:186–96.
Kirsch VC, Orgler C, Braig S, Jeremias I, Auerbach D, Muller R, et al. The cytotoxic natural product vioprolide A targets nucleolar protein 14, which is essential for ribosome biogenesis. Angew Chem Int Ed Engl. 2020;59:1595–600.
Yan F, Auerbach D, Chai Y, Keller L, Tu Q, Huttel S, et al. Biosynthesis and heterologous production of vioprolides: rational biosynthetic engineering and unprecedented 4-methylazetidinecarboxylic acid formation. Angew Chem Int Ed Engl. 2018;57:8754–9.
Itoh Y, Kodama K, Furuya K, Takahashi S, Haneishi T, Takiguchi Y, et al. A new sesquiterpene antibiotic, heptelidic acid producing organisms, fermentation, isolation and characterization. J Antibiot. 1980;33:468–73.
Endo A, Hasumi K, Sakai K, Kanbe T. Specific inhibition of glyceraldehyde-3-phosphate dehydrogenase by koningic acid (heptelidic acid). J Antibiot. 1985;38:920–5.
Sakai K, Hasumi K, Endo A. Identification of koningic acid (heptelidic acid)-modified site in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta. 1991;1077:192–6.
Muroi M, Futamura Y, Osada H. Integrated profiling methods for identifying the targets of bioactive compounds: MorphoBase and ChemProteoBase. Nat Prod Rep. 2016;33:621–5.
Muroi M, Osada H. Proteomic profiling for target identification of biologically active small molecules using 2D DIGE. Methods Mol Biol. 2019;1888:127–39.
Kawatani M, Muroi M, Wada A, Inoue G, Futamura Y, Aono H, et al. Proteomic profiling reveals that collismycin A is an iron chelator. Sci Rep. 2016;6:38385.
Futamura Y, Muroi M, Aono H, Kawatani M, Hayashida M, Sekine T, et al. Bioenergetic and proteomic profiling to screen small molecule inhibitors that target cancer metabolisms. Biochim Biophys Acta. 2019;1867:28–37.
Subedi A, Muroi M, Futamura Y, Kawamura T, Aono H, Nishi M, et al. A novel inhibitor of tumorspheres reveals the activation of the serine biosynthetic pathway upon mitochondrial inhibition. FEBS Lett. 2019;593:763–76.
Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035–44.
Dittus L, Werner T, Muelbaier M, Bantscheff M. Differential kinobeads profiling for target identification of irreversible kinase inhibitors. ACS Chem Biol. 2017;12:2515–21.
Matsumoto M, Matsuzaki F, Oshikawa K, Goshima N, Mori M, Kawamura Y, et al. A large-scale targeted proteomics assay resource based on an in vitro human proteome. Nat Methods. 2017;14:251–8.
Mikawa T, Shibata E, Shimada M, Ito K, Ito T, Kanda H, et al. Phosphoglycerate mutase cooperates with Chk1 kinase to regulate glycolysis. iScience. 2020;23:101306.
Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, et al. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharm Exp Ther. 2001;297:114–20.
Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharm. 2003;52:S74–79.
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–35.
Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, et al. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Cancer Sci. 2015;106:909–20.
Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol. 2009;16:712–23.
Futamura Y, Kawatani M, Kazami S, Tanaka K, Muroi M, Shimizu T, et al. Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. Chem Biol. 2012;19:1620–30.
Piotrowski JS, Li SC, Deshpande R, Simpkins SW, Nelson J, Yashiroda Y, et al. Functional annotation of chemical libraries across diverse biological processes. Nat Chem Biol. 2017;13:982–93.
Acknowledgements
We thank Dr. Julius Lopez for English editing. This work was supported in part by Grant-in-Aid for Scientific Research grant numbers JP21H04720, JP20H05620 and JP20K05857, Grant-in-Aid for Scientific Research on Innovative Areas grant numbers JP17H06412 and JP16H06276, AMED P-CREATE grant number JP20cm0106112h0005.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Muroi, M., Osada, H. Proteomics-based target identification of natural products affecting cancer metabolism. J Antibiot 74, 639–650 (2021). https://doi.org/10.1038/s41429-021-00437-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-021-00437-y